Medicines Company
Medicines Company (17093) develops pharmaceutical products that improve acute hospital care. It is featuring Angiomax (bivalirudin), a thrombin-specific antithrombotic.
Angiomax has been evaluated in six randomized trials of over 25,000 patients undergoing percutaneous coronary intervention and was found to improve clinical outcomes when compared with heparin as a foundation anticoagulant in the contemporary catheterization lab setting.
The Medicines Company meets the demands of medical practitioners by developing pharmaceutical products that improve acute hospital care. The company acquires, develops and commercializes pharmaceutical products in the late stages of their development and creates value using its range of clinical and commercial skills to develop these products.
The Medicines Company is currently developing products for acute hypertension and for acute coronary syndromes.
Angiomax has been evaluated in six randomized trials of over 25,000 patients undergoing percutaneous coronary intervention and was found to improve clinical outcomes when compared with heparin as a foundation anticoagulant in the contemporary catheterization lab setting.
The Medicines Company meets the demands of medical practitioners by developing pharmaceutical products that improve acute hospital care. The company acquires, develops and commercializes pharmaceutical products in the late stages of their development and creates value using its range of clinical and commercial skills to develop these products.
The Medicines Company is currently developing products for acute hypertension and for acute coronary syndromes.